News / Taiwan / economic_daily
Da-Yen Biomedical Q3 Profit Jumps 61.1%, Surpassing Full-Year 2025 Earnings
Health Technology · Biotechnology · economic_daily · 2026-11-09
7780
Da-Yen Biomedical reported a 61.1% year-on-year profit increase for the first nine months, driven by strong core product sales and international expansion.
What Happened
Financial Performance: Da-Yen Biomedical reported a Q3 net profit of NT$110 million, bringing the nine-month total to NT$340 million, a 61.1% increase year-on-year. With an EPS of NT$0.43, the company has already exceeded its total profit for the entire year of 2025.
Revenue Growth: October revenue reached NT$220 million, up 66.8% year-on-year, with cumulative revenue for the first ten months hitting a record high of NT$1.911 billion. This growth is attributed to robust core product sales and successful new product strategies.
Product Strategy: The company continues to focus on its core categories of fish oil, lutein, and probiotics. Recent product launches, such as the ginseng-based nutritional supplement, have been well-received, further strengthening the brand's market position.
Market Expansion: Operations in Japan have shown strong growth through e-commerce channels, driving both new customer acquisition and repeat purchases. The company is now leveraging major promotional events like Singles' Day to capture year-end demand and sustain its growth momentum.